- Home
- SCYX vs TARA Comparison
SCYX vs TARA Comparison
Compare SCYX & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- TARA
- Stock Information
- Founded
- SCYX 1999
- TARA N/A
- Country
- SCYX United States
- TARA United States
- Employees
- SCYX N/A
- TARA N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCYX Health Care
- TARA Health Care
- Exchange
- SCYX Nasdaq
- TARA Nasdaq
- Market Cap
- SCYX 50.3M
- TARA 52.4M
- IPO Year
- SCYX 2014
- TARA N/A
- Fundamental
- Price
- SCYX $1.21
- TARA $2.29
- Analyst Decision
- SCYX Buy
- TARA Strong Buy
- Analyst Count
- SCYX 1
- TARA 2
- Target Price
- SCYX N/A
- TARA $24.00
- AVG Volume (30 Days)
- SCYX 165.3K
- TARA 187.3K
- Earning Date
- SCYX 11-06-2024
- TARA 11-12-2024
- Dividend Yield
- SCYX N/A
- TARA N/A
- EPS Growth
- SCYX N/A
- TARA N/A
- EPS
- SCYX N/A
- TARA N/A
- Revenue
- SCYX $8,566,000.00
- TARA N/A
- Revenue This Year
- SCYX N/A
- TARA N/A
- Revenue Next Year
- SCYX $145.59
- TARA N/A
- P/E Ratio
- SCYX N/A
- TARA N/A
- Revenue Growth
- SCYX N/A
- TARA N/A
- 52 Week Low
- SCYX $1.15
- TARA $1.13
- 52 Week High
- SCYX $3.07
- TARA $5.24
- Technical
- Relative Strength Index (RSI)
- SCYX 28.95
- TARA 48.52
- Support Level
- SCYX $1.25
- TARA $2.21
- Resistance Level
- SCYX $1.37
- TARA $2.74
- Average True Range (ATR)
- SCYX 0.06
- TARA 0.16
- MACD
- SCYX -0.01
- TARA -0.05
- Stochastic Oscillator
- SCYX 9.26
- TARA 14.04
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).